Via Transportation (VIA) shares saw a small uptick today, closing up 2%. With recent trading still in the red for the past month, many investors are watching to see whether this movement marks a shift in sentiment.

See our latest analysis for Via Transportation.

After a tough month for Via Transportation, with a 1-month share price return of -24.54%, today's upward move could be a sign that some investors are reassessing the company's future prospects. While momentum faded through the year to date numbers, this latest uptick hints there may still be room for optimism.

If you’re thinking about branching out beyond VIA, now could be the perfect moment to broaden your search and discover fast growing stocks with high insider ownership

With a sizable discount to analyst price targets and improving fundamentals, questions remain. Is Via Transportation’s current share price undervaluing its long-term growth, or is the recent rally simply the market catching up?

Via Transportation is currently priced at a 7.4x price-to-sales ratio, which stands out as more expensive than both its US Software industry peers and similar companies.

The price-to-sales ratio is a popular metric for fast-growing technology companies when profits are negative or volatile. It reflects how much investors are willing to pay for each dollar of company revenue, providing a sense of the “valuation premium” the market assigns to sales growth potential when there isn’t a profit yet.

For Via, the multiple is significantly higher than the US Software sector average of 4.6x and the peer average of 6.5x. This suggests the market is already pricing in a strong outlook or growth story, even though the company is not yet profitable and there is uncertainty about when it will be. Without data on a “fair” price-to-sales ratio from deeper regression models, this lofty multiple could prove risky if expectations are not met.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-Sales of 7.4x (OVERVALUED)

However, risks remain, such as ongoing net losses and the potential for slower revenue growth. These factors could dampen investor expectations moving forward.

Find out about the key risks to this Via Transportation narrative.

While the price-to-sales ratio points to overvaluation, our SWS DCF model offers a different perspective. According to this method, Via Transportation’s share price is actually trading at a 21.2% discount to its estimated fair value. This raises the question of whether recent pessimism is overdone, or if it reflects a different set of risks.

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Via Transportation for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 923 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

If you have a different perspective or want to explore your own take, it only takes a few minutes to build your personal view. Do it your way

A great starting point for your Via Transportation research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.

Take the guesswork out of your next investment move and supercharge your strategy by tapping into high-potential opportunities other investors are targeting today.

Maximize your income by targeting steady, high-yield opportunities among 3%;elm:context_link;itc:0;sec:content-canvas\\" class=\\"link \\">these 16 dividend stocks with yields > 3%. These consistently reward shareholders.

Amplify your tech exposure with these 26 quantum computing stocks, which are shaping tomorrow’s breakthroughs and redefining what is possible.

Stay ahead of the curve by backing innovation in healthcare through these 30 healthcare AI stocks. These are revolutionizing diagnostics, treatment, and patient care.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include VIA.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com